Dactinomycin Clinical Trials
4 recruitingBiologic
Phase 33Phase 21
Showing 1–4 of 4 trials
Recruiting
Phase 2
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Rhabdomyosarcoma
St. Jude Children's Research Hospital135 enrolled3 locationsNCT06023641
Recruiting
Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Stage I Mixed Cell Type Kidney Wilms TumorStage II Mixed Cell Type Kidney Wilms TumorStage III Mixed Cell Type Kidney Wilms Tumor+1 more
Children's Oncology Group1,656 enrolled159 locationsNCT06401330
Recruiting
Phase 3
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Embryonal RhabdomyosarcomaFusion-Negative Alveolar RhabdomyosarcomaSpindle Cell/Sclerosing Rhabdomyosarcoma
Children's Oncology Group205 enrolled180 locationsNCT05304585
Recruiting
Phase 3
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Pleuropulmonary Blastoma
Children's Oncology Group110 enrolled82 locationsNCT06647953